Sunday, 22 July 2018

Transasia, APPI bring in the latest clinical diagnostic trends

22 June 2018 | News

Transasia offered participants an opportunity to interact with the industry experts while introducing its latest technologies at the conference.

Image credit- wordpress.com

Image credit- wordpress.com

Transasia Bio-Medicals Ltd., India’s leading in-vitro diagnostic company, recently participated in the 5th annual conference by the Association of Practicing Pathologists of India (APPI) held between 16-17 June, 2018 at The Lalit, Mumbai. Transasia offered participants an opportunity to interact with the industry experts while introducing its latest technologies.

The four exclusively organized workshops by Transasia, on Biochemistry, Hematology, Coagulation and Immunology, focused on the latest advancements complete with discussions on first-hand experiences of the participants.

Dr. Rumma Manchanda, Prof. & Dir. of Pathology, KEM Hospital, Pune led the session on ‘Approach to bleeding patients and QC in coagulation in standalone labs.’ Dr. Saravanan, Prof. & Head of Dept. – Biochemistry, Stanley Medical College, Chennai, conducted a refresher module on the ‘Basic Principles of Clinical Chemistry.’ Dr. K. Gayathri, Consultant Pathologist, Lifeline Tapadia Diagnostic Centre, Hyderabad, spoke on ‘CBC on 3 Part/ 5 Part analyzer in standalone laboratories’ while Dr. Gita Nataraj, Prof. –Dept. of Microbiology, KEM Hospital, Mumbai  shared a status update on Dengue fever.

On behalf of Transasia, Dr. Ameeta Joshi, Prof.- Dept. of Microbiology, JJ Hospitals, Mumbai conducted the plenary session addressing the ‘Challenges and solutions in diagnosis of Tuberculosis’. The session laid emphasis on the newer technologies, particularly in Molecular diagnostics, for TB detection.

Transasia has been taking concerted efforts in this direction with its soon to be launched comprehensive portfolio for molecular testing for diseases such as HIV, TB, respiratory diseases, dengue, malaria, etc.

Besides this, Transasia also introduced its new technologies in Clinical Chemistry and Immunology. XL 1000 is the latest, random access clinical chemistry analyzer with a throughput of 1040 tests/ hr. Its other key features as sample clot detection, permanent hard glass cuvettes, four channel direct ISE measurement, 3 reagent capability, simultaneous placement of up to 150 samples, among others, make it an ideal choice for high volume laboratories.

ErbaQik rapid test kits for dengue and malaria were introduced by Transasia at the apt time, considering the need to contain the infections during monsoon. With a unique dual colour advantage, it is the only bi-colour detection immuno-chromatographic device. Unmatched sensitivity of > 92% and specificity of 100% for all parameters of dengue and malaria, makes it the most reliable in India today.  

Additionally, Transasia also showcased its best offerings in Clinical Chemistry, Urinalysis, Coagulation and Hematology.

Over 500 practicing pathologists form India and across the globe participated during the two day event making it a huge success.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Is Telemedicine a key component that will help bring down the disparity in health offerings between rural and urban India?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls